论文部分内容阅读
二肽基肽酶Ⅳ抑制剂能抑制二肽基肽酶Ⅳ的活性,从而减少胰高血糖素样肽1、葡萄糖促胰岛素多肽、垂体腺苷酸环化酶激活多肽等的降解,促进胰岛素分泌,在降低血糖的同时具有保护β细胞功能的作用,且不会引起低血糖、体重增加等副作用,有望发展成为新的口服降糖药。
Inhibitors of dipeptidyl peptidase IV inhibit the activity of dipeptidyl peptidase IV, thereby reducing the degradation of glucagon-like peptide 1, glucose-promoting insulin polypeptide, pituitary adenylate cyclase activating polypeptide, etc., and promote insulin secretion , It has the function of protecting β-cell function while lowering blood sugar, and will not cause side effects such as hypoglycemia and weight gain, and is expected to develop into a new oral hypoglycemic drug.